Pasar al contenido principal

Immune4ALL. Explorando la viabilidad de biomarcadores predictivos y farmacodinámicos de inmunoterapia en tumores sólidos

PMP22/00054

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Convocatoria Proyectos de Investigación de Medicina Personalizada de Precisión
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER)
Centro realización CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Mies, Belén
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene|||0000-0003-1986-2965
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana|||0000-0001-7763-320X
  • D'Angelo, Emanuela|||0000-0002-6173-1806
  • Hardisson, David|||0000-0002-2183-3699
  • Vieites, Begoña
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Estévez-García, Purificación
  • Guerra, Eva|||0000-0003-1910-4451
  • Prat, Jaime|||0000-0002-9787-3304
  • Poveda, Andrés
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Palacios, José|||0000-0002-6730-5066
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Grinyó-Escuer, Ariadna|||0000-0003-0185-2734
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Rius-Ruiz, Irene
  • Bort-Brusca, Marta
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Maqueda-Marcos, Susana
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Gago, Judit
  • Nogales, Vanesa
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Soucek, Laura|||0000-0002-4750-7971
  • Braña, Irene|||0000-0002-1068-9601
  • Galvao, Vladimir
  • Martín-Lluesma, Silvia|||0000-0001-7491-1876
  • Moessner, Ekkehard
  • Klein, Christian|||0000-0001-7594-7280
  • Garralda, Elena|||0000-0002-4412-7842
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chimeric antigen receptor T (CAR-T) cell therapy is efficient in certain haematologic malignancies, but clinical success in solid tumours has been hampered by scarcity of tumour-specific antigens. Here authors show that combination therapy using CAR T cells targeting p95HER2 and bispecific antibodies against HER2 and CD3 consistently leads to complete regression in HER2-positive, patient-derived xenografts tumours in mouse models.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Míes, Belén
  • Redondo, Andrés
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana
  • D’Angelo, Emanuela
  • Hardisson, David
  • Vieites, Begoña
  • Matías-Guiu, Xavier
  • Estévez-García, Purificación
  • Guerra, Eva
  • Prat, Jaime
  • Poveda, Andrés
  • López-Guerrero, José Antonio
  • Palacios Calvo, José
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (>20 TILs/core), low/intermediate CD4+ (<20 TILs/core) and high CD8+/CD4+ ratio (>35/core) were associated with favorable outcomes. Tumor cell PD-L1 expression (TPS ≥ 1) was present in only 8% of tumors. In total, 11 (16%) and 6 (9%) out of 69 HGSOC tested carried pathogenic or likely pathogenic BRCA1 or BRCA2 mutations, respectively. Median TMB of 40 tumors analyzed was 5.04 mutations/Mb and only 6 tumors had 10 or more mutations/Mb. BRCA status and TMB were not associated with TILs or prognosis. When compared with studies on advanced HGSOC, our results suggested that prognostic variables differed according to stage and that more studies focused on early stages of HGSOC are needed to better stratify these tumors., This work was supported by Instituto de Salud Carlos III (ISCIII) (grants PI19/01331, PI22/01892 and PMP22/00054); CIBERONC (grant CB16/12/00316); European Development Regional Fund ‘A way to achieve Europe’ (FEDER), Spanish Group of Research in Ovarian Cancer (GEICO group); and by the Spanish Association Against Cancer Scientific Foundation (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation

  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
  • Vargas Padilla, María Victoria
  • Lobo Selma, Laura
  • Chacón-Barrado, Antonio
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings., E.d.Á. laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to E.d.Á., Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to E.d.Á., ECAEC222952DEAL, Fundación Científica AECC to E.d.Á, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to F.O. Fundación Domingo Martínez to F.O. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to D.D.-B. Fundación Getthi ONC18PE01/2022 to E.d.Á., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

  • Olmedo-Pelayo, Joaquín
  • Granado-Calle, Esperanza
  • Delgado-Bellido, Daniel
  • Lobo Selma, Laura
  • Jordán-Pérez, Carmen
  • Monteiro-Amaral, Ana T.
  • Ehlers, Anna C.
  • Ohmura, Shunya
  • García-Domínguez, Daniel
  • Mackintosh, Carlos
  • Carcaboso, Ángel M.
  • Alonso García de la Rosa, Francisco Javier
  • Machado, Isidro
  • Llombart-Bosch, A.
  • Scotlandi, Katia
  • Grünewald, Thomas G. P.
  • Gómez-Herreros, Fernando
  • Álava, Enrique de
Drug resistance is an ill-defined cause of dismal outcomes in cancer. Ewing sarcoma (EwS), a pediatric cancer characterized by high therapy failure rates, is driven by a single oncogenic event generating EWSR1::ETS gene fusions (primarily EWSR1::FLI1) in a silent genomic background. This provides a straightforward model to study the impact of gene fusions on drug responses. Here, we describe a novel mechanism of sensitivity to DNA topoisomerase 1 poisons in EwS. We discovered that EWS::FLI1 prevents the resolution of R-loops induced by these drugs via sequestering DHX9 helicase, ultimately resulting in R-loop accumulation, replication stress, and genome instability. In turn, excessive DHX9 or reduced EWS::FLI1 levels render EwS cells resistant to the active metabolite of irinotecan (SN-38) independent of proliferation and global transcription rates. This resistance helps explain how elevated DHX9 levels predict worse clinical outcomes. Overall, our research demonstrates the impact of a dominant mutation on cancer drug sensitivity, highlighting its significant clinical implications., JO-P is supported by Ph.D. grant Plan Propio from the University of Seville. DD-B is supported by Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_21_00865). DJG-D was supported by the VII Plan Propio de Investigación y Transferencia de la Universidad de Sevilla [Contrato de Acceso (II.4)/VII PPIT-US]. The laboratory of JA is supported by Instituto de Salud Carlos III (grant numbers PI20CIII/00020, DTS22CIII/00003, PMP21-00073); Asociación Pablo Ugarte (TRPV205/18, DGDO195722); Asociación Candela Riera, Asociación Todos Somos Iván & Fundación Sonrisa de Alex (TVP333-19, TVP-1324/15). The laboratory of TGPG is supported by grants from the Matthias-Lackas Foundation, the Dr. Leopold und Carmen Ellinger Foundation, the Deutsche Forschungsgemeinschaft (DFG 458891500), the German Cancer Aid (DKH-7011411, DKH-70114278), the Boehringer-Ingelheim foundation, the Dr. Rolf M. Schwiete foundation, the SMARCB1 association, the Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA) and the Barbara and Wilfried Mohr foundation. A.C.E. was supported by a scholarship from the German Cancer Aid. The laboratory of FG-H is supported by grants funded by MCIN/AEI/10.13039/501100011033/FEDER, UE (R + D + i PID2019-105212GB-I00 and PID2022-137143NB-I00) and the Andalusian Regional Government: Fondo Europeo de Desarrollo Regional (FEDER) y Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (P20_00561) to FG-H. The laboratory of EdA is supported by grants from ISCIII-FEDER (PI20/00003, PI23/1460 and PMP22/00054), Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018, PI-0061-2020), Fundación Científica AECC (ECAEC222952DEAL), Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC Instituto de Salud Carlos III, CB16/12/00361., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.